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Abstract
Cancer results from alterations at essential genomic sites and is characterized by uncon-
trolled cell proliferation, invasion and metastasis. Identification of driver genes of metastatic
progression is essential, as metastases, not primary tumors, are fatal. To gain insight into
the mutational concordance between different steps of malignant progression we performed
exome sequencing and validation with targeted deep sequencing of successive steps of
malignant progression from pre-invasive stages to asynchronous distant metastases in six
breast cancer patients. Using the ratio of non-synonymous to synonymous mutations, a sur-
prisingly large number of cancer driver genes, ranging between 3 and 145, were estimated
to confer a selective advantage in the studied primary tumors. We report a substantial
amount of metastasis specific mutations and a number of novel putative metastasis driver
genes. Most notable are the DCC, ABCA13, TIAM2, CREBBP, BCL6B and ZNF185 genes,
mainly mutated exclusively in metastases and highly likely driver genes of metastatic pro-
gression. We find different genes and pathways to be affected at different steps of malignant
progression. The Adherens junction pathway is affected in four of the six studied patients
and this pathway most likely plays a vital role in the metastatic process.
Introduction
Cancer evolves through the stochastic, cumulative acquisition of driver mutations disrupting
key pathways leading to the hallmarks of cancer [1]. A cancer driver mutation confers a selec-
tive advantage, while passenger mutations are coexisting mutations in the successfully expand-
ing clones [2]. The cancer genome evolves dynamically influenced by the generation of
additional mutations and selective forces acting on cancer clones, the latter being time and site
dependent. The term oncogene addiction [3] describes the cancer cell dependence of particular
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driver genes for maintenance of the malignant phenotype and provides the rationale for tar-
geted therapy. One of the major challenges in cancer genetics is to identify cancer driver genes.
Mutations in the coding region can be divided into synonymous, also known as silent
mutations, and non-synonymous mutations. Typically, nucleotide substitutions in the third
codon position are silent, whereas substitutions in the first and second codon positions result
in an amino acid change. The ratio of non-synonymous to synonymous mutations (NS:S
ratio) has been used as a reliable indicator of selection. Two factors influence the NS:S ratio,
including the rate of creation and the selective forces acting on them. In the absence of selec-
tion, non-synonymous and synonymous mutations are equally likely to persist [4] and thus
the NS:S ratio can indicate whether or not selection is occurring.
The metastatic process is highly complex and not yet fully understood. The main bottleneck
for metastasis formation is believed to be colonization at the distant site [5]. A solid tumor is
suggested to infiltrate into the circulatory system one million cancer cells per day [6] and
tumor cells are found to disseminate systemically even from pre-invasive tissue [7]. Thus, addi-
tional genetic, epigenetic or host response events are needed in order to allow a disseminated
tumor cell to create a metastatic lesion. Identification of specific driver genes of the metastatic
process is to a large degree limited to the yet relatively few identified metastasis suppressor
genes [8]. A reduced expression of a metastasis suppressor gene does not provide a selective
advantage in the primary tumor, but plays a major role in the metastatic process [9]. Based on
their level of participation in different steps of the metastatic process different classes of metas-
tasis genes have been suggested: metastasis initiation genes, metastasis progression genes and
metastasis virulence genes [10]. In addition to acquiring abilities like detachment, motility,
invasion, intravasation, survival in the circulation and adaptation to new environment the
malignant cell must be able to evade immune surveillance. Microenvironmental factors like
acidity and hypoxia also provide selective forces upon the cancer clones [2]. Thus, the driving
capacity of mutations is site dependent, inducing genetic disparity between a primary tumor
and its metastases. Therapy-induced eradication of the dominant, chemotherapy- and anti-
hormonal therapy sensitive clones serves to increase the selective pressure within the malig-
nant cell population, leading to expansion of therapy-resistant clones. Hence, the location of a
recurrence and treatment influences molding of the cancer genome at the distant site. Due to
increasing genomic instability and stochastic events [9] cancer genome evolution must be
expected to continue also in disseminated tumor cells after removal of the primary tumor.
In a recent study, including only two breast cancer patients, gene expression signatures,
DNA copy number patterns and somatic mutation patterns were found to be highly similar
across primary tumors and matched metastases [11]. In another study, including 11 patients, a
high concordance of chromosomal rearrangements was found between primary tumors and
matched metastases [12].
Mutational discordances between a primary tumor and its metastases may identify new
driver genes of metastatic progression and provide insight into the biology underlying meta-
static progression. In our study, we have used exome and deep targeted sequencing of pre-
invasive stages, primary tumors, synchronous axillary lymph node (ALN) metastases and asyn-
chronous distant metastases from six breast cancer patients to identify putative novel driver
genes of metastatic progression and to identify pathways involved in metastasis.
Materials and methods
Patient material
The study includes successive tumor samples from six breast cancer patients with estrogen
receptor (ER) positive invasive ductal carcinoma. Table 1 displays clinical information of the
Breast cancer metastasis driver genes
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patients. All patients had ALN metastases at the time of diagnosis and primary tumors from all
patients and synchronous ALN metastases from five of the patients were secured during pri-
mary surgery and stored at -80˚C until sample preparation. In three cases, also pre-invasive
stages, Ductal Carcinoma in Situ (DCIS) were secured during primary surgery. In one case,
Patient ID (PTID) 8, we had access to two different regions of DCIS and in one case, two dif-
ferent regions of primary tumor (PTID 4). In spite of adjuvant therapy, four of the patients
experienced recurrence of the disease, with a median relapse time of 3.08 years, and asynchro-
nous metastases were biopsied from bone, lymph node and in two cases liver, respectively.
Haematoxylin-eosin sections of all tissue samples were reviewed by a certified pathologist,
ensuring the diagnosis and a content of malignant cells of 50% at minimum. A start amount of
20–30 mg fresh frozen tissue (asynchronous metastasis 5 mg) was used for the purification
process. Tissue disruption and homogenization was performed using TissueLyser (Qiagen)
and purification of DNA was performed using AllPrep DNA/RNA Mini Kit (Qiagen).
Matched normal tissue and the primary tumor of PT ID 8 were stored as formalin-fixed paraf-
fin-embedded (FFPE) tissue. The FFPE blocks were cut in 30–40 sections of 10 μm and DNA
extracted using AS1000 Maxwell 16 (Promega, USA).
Additional analyses of the data have been described in [13] and [14].
The patients provided written informed consent to participate in the study and for the data
to be published. The study was approved by the Ethical Committee of Region Syddanmark
and notified to the Danish Data Protection Agency.
Library construction and exome sequencing
One microgram of genomic DNA from each sample was randomly fragmented by focused
acoustic shearing (Covaris inc.) according to Illumina’s protocol. The fragment length was
measured by Bioanalyzer (Agilent Technologies 2100), confirming a fragment length of 150–
300 bp. Exome enrichment was performed with Illumina’s TruSeq DNA Sample Preparation.
Paired end sequencing of 2 x 100 bases was performed on the Illumina HiSeq 1500 platform.
FASTQ files were aligned to the human reference genome GRCh37 (feb.2009) using the
Novoalign v. 3 algorithm (www.novocraft.com) at default parameters. Removal of duplicate
reads, recalibration and local realignment around indels were performed using Best Practices
Table 1. Patient characteristics.
Pt
ID
Age Type Primary size ER PR HER 2 MG # pos LN Relapse time Treatment
4 72 years IDC 14 mm pos neg A II 1/10 LN 1.82 years Surgery, adjuvant Letrozole.
8 58 years IDC 50 mm pos pos N II 15/15 LN 4.05 years 5 series of neo-adj. CEF, surgery, 4 series of Taxotere/
Gemcitabine. Tamoxifen 2.5 years, then Arimidex, radiation
therapy
11 46 years IDC 25 mm pos pos N III 1/15 LN 2.57 years Surgery, adjuvant 7 series of CEF, Tamoxifen, radiation
therapy.
15 66 years IDC 17 mm + 15
mm = multifokal
pos pos N III 17/18 LN 3.90 years Surgery, adjuvant Letrozole, radiation therapy.
46 79 years IDC 10 mm and diffusely
spread 110 mm
pos neg N III 5/20 LN Neo-adjuvant Letrozole, surgery.
123 67 years IDC 23 mm pos neg A II 5/11 LN Surgery.
IDC: Invasive ductal carcinoma. ER: Estrogen receptor status. MG: Malignancy grade. PR: Progesterone receptor status. N: normal. A: amplified. CEF: Cyclofosfamid,
Epirubicin, 5- Flouracil. LN: lymph nodes.
https://doi.org/10.1371/journal.pone.0189887.t001
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pipeline v. 2.7 [15]. The result was a mean coverage rate in the exome region of 65–155 x in the
tumor samples and 11–148 x in the matched normal samples (S1 Table).
Detection of putative somatic mutations for deep sequencing
On the exome sequencing data, somatic variant calling was performed using nine publicly
available somatic variant callers: EB Call [16], Mutect [15], Seurat [17], Shimmer [18], Indelo-
cator (http://www.broadinstitute.org/cancer/cga/indelocator), Somatic Sniper [17], Strelka
[19], Varscan 2 [20] and Virmid [21]. The union of putative somatic mutations, except posi-
tions in intronic, intergenic, downstream and non-coding RNA intronic areas, reported by the
nine somatic variant callers was used to select chromosomal candidate regions for targeted
deep sequencing.
Validation with targeted deep sequencing
Target enrichment was performed using SureSelect DNA enrichment methodology (Agilent).
A custom SureSelect enrichment kit was designed using the Agilent SureDesign application.
Library construction and SureSelect enrichment were performed according to manufacturer’s
protocol and sequenced on the Illumina HiSeq 1500 platform with paired end sequencing 2 x
100 bases. Deep sequencing resulted in a mean coverage of 221–628 x of the targeted positions
(S2 Table). Alignment and data preprocessing were performed as described previously. Variant
calling were performed using Varscan 2 [20] version 2.3.6 (multisample setting). For each
patient the following criteria were used: normal sample B Allele Frequency (BAF) less than
0.02, all samples should have a read depth of min. 50 x and BAF in one of the tumor samples
should be 0.05 at minimum. For positions meeting those criteria, a mutation found with a BAF
of 0.025 at minimum was included in other tumor samples if read depth exceeded 200 x. The
variants were annotated with Annovar [22] and only exonic and splicing variants were included
for further analysis. Known SNPs with a population allele frequency> 1% were excluded.
Subsequently, all identified somatic mutations within the coding region were manually
curated, by visual inspection of the BAM files to remove false positive calls. Variants located in
a repetitive area and variants with many adjacent variants were excluded, as they most likely
result from systematic misalignment. Furthermore, unrelated BAM files were compared to the
patient BAM files in order to identify error prone regions.
Pathway analysis of genes involved in different steps of malignant
progression
The non-synonymous and splice site mutations were divided into three categories:
1. Mutations found exclusively in DCIS and primary tumors.
2. Mutations shared between primary tumors and metastases.
3. Mutations found exclusively in metastases.
Pathway analysis for overrepresentation of genes in KEGG gene sets (http://www.genome.
jp/kegg/) were computed for each category of genes using the online tool Molecular Signatures
Database by Broad Institute [23,24].
Identification of putative novel driver genes of metastatic progression
In order to prioritize among the many missense mutations, the iCAGES software tool (http://
icages.usc.edu) was used in order to facilitate the distinction between driver and passenger
Breast cancer metastasis driver genes
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mutations. The iCAGES prioritization of putative cancer driver variants uses a radial Support
Vector Machine (SVM) based on nine functional prediction tools (SIFT, PolyPhen-2, GERP+
+, FATHMM, Mutation Taster, Mutation Assessor, Siphy, PhyloP, LRT) which is trained on
somatic non-synonymous SNVs from the Catalogue Of Somatic Mutations In Cancer (http://
cancer.sanger.ac.uk/cancergenome/projects/cosmic) and the Uniprot databases (http://www.
uniprot.org). The resulting radial SVM predicted score evaluates the cancer driver potential
for each particular mutation. Additionally the iCAGES tool incorporates a Phenolyzer score
evaluating the genetic-phenotypic association based on previous database knowledge (http://
phenolyzer.usc.edu). A total weighed score, iCAGES score, ranks each mutation according to
cancer driver potential.
Putative novel drivers of malignant progression were selected by the following criteria:
Classified as a cancer driver gene by the iCAGES software or affected by a frameshift, stopgain
or splicing mutation.
Results
Varying mutational concordance among the analyzed patients
A large variation in the number of mutations in the coding region of the studied patients was
found. A total of 31–418 non-synonymous and splicing mutations and 13–113 synonymous
mutations were identified by exome sequencing and validated by targeted deep sequencing in
the six patients included in the study. The complete lists of validated somatic mutations in the
coding region of the six studied patients are available in S3–S8 Tables. Venn diagrams display-
ing the mutational concordance of non-synonymous and splice site mutations between differ-
ent steps of malignant progression are shown in Fig 1. The patients display varying degree of
genetic concordance between different steps of progression. The majority of mutations are
shared between primary tumors and metastases, however, a significant number of mutations
are exclusive to the metastases of the studied patients.
The ratio of non-synonymous and synonymous mutations indicates a
considerable number of driver genes
The number of non-synonymous (NS) and synonymous (S) mutations identified in the pri-
mary tumors of each patient are shown in Table 2. NS:S ratios in four of the six studied pri-
mary tumors are significantly higher than the NS:S ratio of 2:1 predicted for non-selected
passenger mutations. For the remaining two primary tumors, the numbers are probably too
small to reach significance. The number of cancer driver mutations, conferring a selective
advantage to the malignant cells, can be calculated as the number of non-synonymous muta-
tions exceeding the expected ratio of 2:1. With reservations for our assumptions, the number
of driver genes in the primary tumors included in our study varies between 3 and 145 (S9
Table). The NS:S ratios for ALN metastases specific mutations collectively reaches statistical
significance (Table 3), while the mutations specific to the asynchronous metastases do not
reach the normally accepted statistical significance level of 5%.
Recurrently mutated genes in metastatic progression
A number of genes are recurrently mutated within individual patient samples and across the
six studied patients as seen in Tables 4 and 5, respectively. Some of the genes are already estab-
lished as cancer related genes as they are present in the Catalogue Of Somatic Mutations In
Cancer (COSMIC) Cancer Gene Census list (http://cancer.sanger.ac.uk/cancergenome/
projects/census/) while the remaining genes may include novel cancer driving genes.
Breast cancer metastasis driver genes
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Fig 1. Genomic concordance. Venn diagrams depicting the genomic concordance of non-synonymous and splice site mutations
between different steps of progression in the six studied patients.
https://doi.org/10.1371/journal.pone.0189887.g001
Table 2. Non-synonymous and synonymous mutations present in the primary tumors.
PT ID 4 PT ID 8 PT ID 11 PT ID 15 PT ID 46 PT ID 123
Non-synonymous 177 48 117 29 335 65
Synonymous 47 16 42 13 95 21
Ratio 3.76 3.0 2.78 2.23 3.52 3.09
P-value 0.00003 0.097 0.036 0.44 2.08 E 10−7 0.047
P-values are calculated by one-tailed binomial test.
https://doi.org/10.1371/journal.pone.0189887.t002
Breast cancer metastasis driver genes
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Table 3. Non-synonymous and synonymous mutations specific for mutations in ALN metastases and asynchro-
nous distant metastases, respectively, collectively for the six studied patients.
ALN metastasis specific mutations Asynchronous distant mutation specific mutations
Non-synonymous 50 92
Synonymous 15 35
Ratio 3.33 2.62
P-value 0.049 0.097
P-values are calculated by one-tailed binomial test.
https://doi.org/10.1371/journal.pone.0189887.t003
Table 4. Recurrently mutated genes within individual patient samples.
Cosmic
CGC
Patient ID
4
Patient ID 8 Patient ID
11
Patient
ID 15
Patient ID 46 Patient ID 123
Gene PT
1
PT
2
ALNM DM DCIS
1
DCIS
2
PT ALNM DM PT ALNM DM PT DM DCIS PT ALNM DCIS PT ALNM
MUC4 6x 6x x
FREM2 3x 3x
BRCA2 yes 2x 2x 2x 2x
TTN x x 2x
USHBP1 3x
WAC 3x 3x 3x
XIRP2 3x
AKAP9 yes 2x x x
ARHGAP21 2x 2x 2x 2x
ARMC5 2x 2x 2x 2x
BRD2 x 2x 2x
C1orf63 2x 2x 2x 2x
CAMK2A 2x 2x 2x 2x
F5 2x 2x 2x 2x
FCGBP x 2x
IL6ST yes 2x x x
KIAA1731 2x 2x 2x
LRP1 2x 2x 2x
METTL22 2x 2x 2x
PCDHB16 2x 2x
PLAT 2x 2x 2x
PTPRK yes 2x 2x 2x
RIC8A 2x 2x 2x
RUNX1 yes 2x 2x 2x
TFRC yes x 2x 2x
TIAM2 2x
UGGT2 x2 x2 x2
ZNF469 2x
ABCA13 3x 3x 3x
Only non-synonymous and splice site mutations are included. Cosmic CGC: Included in the Cosmic Cancer Gene Census. x: one mutation. 2x: two mutations. 3x: three
mutations. 6x: six mutations. DCIS: ductal carcinoma in situ. DM: asynchronous distant metastasis. PT: patient. ALNM: axillary lymph node metastasis.
https://doi.org/10.1371/journal.pone.0189887.t004
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Different gene sets are mutated at different steps of malignant progression
The genes affected by non-synonymous and splice site mutations in the six studied patients
were divided into three categories based on the steps of malignant progression in which they
appear. The genes included in Categories 1–3 are listed in S10 Table. Pathway analysis on the
three categories of genes revealed that different pathways are involved in the different steps of
Table 5. Recurrently mutated genes across patients.
Cosmic
CGC
Patient ID
4
Patient ID 8 Patient ID
11
Patient
ID 15
Patient ID 46 Patient ID
123
Gene PT 1 PT 2 ALNM DM DCIS 1 DCIS 2 PT ALNM DM PT ALNM DM PT DM DCIS PT ALNM DCIS PT ALNM
TP53 yes x x x x x x x x x x x
KIAA1033 x x x x x x x x x x x
TNXB x x x x x x x x
WDFY4 x x x x x x x x
PCDHGA1 x x x x x x x
MAN2C1 x x x x x x
MYO3A x x x x x x x
RUNX1 yes x x x x 2x 2x 2x
BRCA2 yes 2x 2x 2x 2x x x x
YY1AP1 x x x x x x x
STK4 x x x x x x x
LRRK1 x x x x x x x
SLC41A2 x x x x x x
CDH23 x x x x x
ZNF827 x x x x x x
ABCA13 x x 3x 3x 3x
LTN1 x x x x x
UNC80 x x x x
PIK3CA yes x x x x x x
APLF x x x x x
BAI3 x x x x
C4orf21 x x x x x
DCC x x
DNAH11 x x x x x
DYNC2H1 x x x x x x
KLHL32 x x x x
NXNL2 x x x x x x
PTPN14 x x x x x x
ROS1 yes x x x x
SGCE x x x x x x
SON x x x x x x
TLN2 x x x x
UTP20 x x x
VWF x x x
FLG x x x x
UBE2O x x x
Includes only non-synonymous and splice site mutations. Cosmic CGC: Included in the Cosmic Cancer Gene Census. x: one mutation. 2x: two mutations. 3x: three
mutations. DCIS: ductal carcinoma in situ. DM: asynchronous distant metastasis. PT: patient. ALNM: axillary lymph node metastasis.
https://doi.org/10.1371/journal.pone.0189887.t005
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malignant progression. In Category 1, including 147 genes found to be mutated exclusively
in pre-invasive tissue or primary tumors, the top five KEGG pathways included Homologous
recombination and Mismatch repair pathways among others, as shown in Table 6.
Category 2, including 606 genes mutated in primary tumors and matched metastases, is sig-
nificantly enriched for genes on various cancer related pathways, as seen in Table 7. Pathway
analysis on the 129 metastasis specific genes in Category 3 reveals that the top three pathways,
although not reaching statistical significance levels, are KEGG Adherens junction, KEGG Ubi-
quitin mediated proteolysis and KEGG Wnt signaling pathway Table 8. These pathways are
likely to be key participants in the metastatic process. Three genes, NLK (PTID 8), CREBBP
(PTID 4), CTNN2A (PTID11) are involved in the KEGG Adherens junction pathway and thus
this pathway is affected in the distant metastases of three of the patients, as seen in Fig 2. Three
Table 6. Results from overlap analyses, Category 1. Pathway analysis of genes mutated exclusively in DCIS and pri-
mary tumors, 147 in total.
Pathways Genes in overlap p-value FDR q-value
KEGG Homologous recombination (28) 4 1.94 E -6 3.6 E -4
KEGG Steroid hormone biosynthesis (55) 3 7.45 E -4 6.93 E -2
KEGG Primary bile acid biosynthesis (16) 2 1.18 E -3 7.34 E -2
KEGG Mismatch repair (23) 2 2.46 E -3 1.14 E -1
KEGG Dilated cardiomyopathy (92) 3 3.27 E -3 1.22 E -1
(#): number of genes in pathway. FDR: false discovery rate.
https://doi.org/10.1371/journal.pone.0189887.t006
Table 7. Results from overlap analyses, Category 2. Pathway analysis of genes mutated in primary tumors and corre-
sponding metastases, 606 in total.
Pathways Genes in overlap p-value FDR q-value
KEGG Neutrophin signaling pathway (126) 13 1.41 E -8 2.62 E -6
KEGG Chronic meyloid leukemia (73) 10 4.35 E -8 4.05 E -6
KEGG Pathways in cancer (328) 19 1.02 E -7 6.35 E -6
KEGG Endometrial cancer (52) 8 3.94 E -7 1.75 E -5
KEGG Focal adhesion (201) 14 5.51 E -7 1.75 E -5
KEGG Steroid hormone biosynthesis (55) 8 6.16 E -7 1.75 E -5
KEGG MAPK signaling pathway (267) 16 6.6 E -7 1.75 E -5
KEGG Glioma (65) 8 2.28 E -6 4.83 E -5
KEGG ERBB signaling pathway (87) 9 2.34 E -6 4.83 E -5
KEGG Complement and coagulation cascades (69) 8 3.6 E -6 6.7 E -5
KEGG Non-small cell lung cancer (54) 7 6.93 E -6 1,17 E -4
KEGG Insulin signaling pathway (137) 10 1.51 E -5 2.35 E -4
KEGG Colorectal cancer (62) 7 1.76 E -5 2.52 E -4
KEGG Calcium signaling pathway (178) 11 2.74 E -5 3.64 E -4
KEGG Thyroid cancer (29) 5 3.58 E -5 4.44 E -4
KEGG Pancreatic cancer (70) 7 3.91 E -5 4.55 E -4
KEGG GnRH signaling pathway (101) 8 6.02 E -5 6.33 E -4
KEGG B cell receptor signaling pathway (75) 7 6.12 E -5 6.33 E -4
KEGG Acute myeloid leukemia (60) 6 1.4 E -4 1.37 E -3
KEGG Prostate cancer (89) 7 1.81 E -4 1.69 E -3
(#): number of genes in pathway. FDR: false discovery rate.
https://doi.org/10.1371/journal.pone.0189887.t007
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Table 8. Results from overlap analyses, Category 3. Pathway analysis of genes mutated exclusively in metastases,
129 in total.
Pathways Genes in overlap p-value FDR q-value
KEGG Adherens junction (75) 3 1.26 E -3 2.34 E -1
KEGG Ubiquitin mediated proteolysis (138) 3 7.03 E -3 4.43 E -1
KEGG Wnt signaling pathway (151) 3 8.99 E -3 4.43 E -1
(#): number of genes in pathway. FDR: false discovery rate.
https://doi.org/10.1371/journal.pone.0189887.t008
Fig 2. KEGG Adherens junction pathway, which is affected exclusively in the metastases of three of the studied patients (gene names in red), and
affected by shared mutations between primary tumor and metastasis in one patient (gene names in blue). CTNNA2 and CTNNA3 are both
encoding α-catenins. Patient IDs are in brackets.
https://doi.org/10.1371/journal.pone.0189887.g002
Breast cancer metastasis driver genes
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genes, MAPK1, SMAD4 and CTNNA3, also belonging to the Adherens junction pathway are
affected by mutations in both primary tumor and metastasis of a fourth of the studied patients
(PTID 46). Pathway analysis including genes mutated in both Category 2 and Category 3
reveals the Adherens junction pathway to be significantly affected (FDR q value 6.08 E -3) in
the primary tumors and metastases of the studied patients.
Putative novel drivers of metastatic progression can be found among genes
affected by metastasis specific mutations and mutations shared between
primary tumors and metastases
Exclusively in the metastases, 142 non-synonymous and splice site mutations were found.
Among these, 45 mutations in 43 genes are classified as putative progression drivers as they
are affected by splice site, stopgain or frameshift mutations or a missense mutation classified as
an iCAGES driver mutation. The putative drivers of progression among the genes mutated
exclusively in the metastases of the studied patients are listed in Table 9. Some of the genes are
already present in the Cancer Gene Census list or KEGG cancer pathway (http://www.
genome.jp/kegg-bin/show_pathway?hsa05200) while other genes may represent novel drivers
of malignant progression. Several of the genes are likely cancer progression genes, based on lit-
erature review, while other genes have not (yet) been described in relation to cancer.
Category 2, including genes affected by shared mutations between primary tumors and
metastases, includes 692 mutations. Among these, 206 mutations are classified as putative
metastasis progression driver genes as they are affected by splice site, stopgain or frameshift
mutations or a nonsynonymous missense mutation classified as an iCAGES driver mutation.
The putative driver genes of metastatic progression from Category 2 can be found in S11
Table.
Discussion
The present study reports substantial variation in the number of mutations within the coding
region and varying mutational concordance between different steps of malignant progression
in the studied breast cancer patients.
A key challenge in cancer genetics is to distinguish between driver and passenger muta-
tions. The identified high NS:S ratios in our study imply positive selection of non-synonymous
mutations in the studied primary tumors and thereby indicate that a surprisingly large propor-
tion of the identified genes have functional significance. This is in concordance with signifi-
cant enrichment in Category 2 of genes involved in many cancer related pathways. The
number of calculated driver mutations in the primary tumors included in our study varies
greatly, ranging between 3 and 145. Other studies have attempted to estimate the number of
driver mutations in solid tumors like breast cancer and suggested up to 20 driver mutations
[25,26]. Supporting the notion of many driver genes, it is estimated, that each driver mutation
confers only a small selective growth advantage to the cell in the order of 0.4% [27]. Progres-
sion from early tumor stages to metastatic lesions is an evolutionary process and metastatic
capacity most likely results from multiple alterations, each providing a slight selective advan-
tage at the different steps of metastasis.
We present putative novel drivers of metastatic progression from the category of genes
mutated exclusively in the metastases of the studied patients (Category 3). One could argue
that metastasis promoting mutations may also be present in the mutations shared between pri-
mary tumors and metastases (Category 2) as it seems likely that metastatic abilities, at least the
ones required for the early steps of the metastatic process, metastasis initiation genes, are pres-
ent in the cells prior to dissemination from the primary tumor. However, only clonally
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Table 9. Putative drivers of metastatic progression from Category 3, metastasis specific mutations.
PT ID 4 Gene CytoBand Mutation type cDNA change AA change Category iCAGES ALNM BAF DM BAF
LAMB3 1q32.2 S c.1132+2T>G x x
DUSP10 1q41 NS c.335A>C p.Q112P Yes x x
IL1RAP 3q28 FS del c.295_302del p.99_101del x x
ABCA13 7p12.3 FS del c.7112delG p.R2371fs x x
CREBBP 16p13.3 NS c.4357C>A p.Q1453K CGC Yes x x
GTF2F1 19p13.3 NS c.808G>C p.E270Q Yes x x
BCL6B 17p13.1 FS del c.1176_1185del p.392_395del x x
ZNF185 Xq28 S c.1971+2T>A x x
ACADM 1p31.1 NS c.271A>T p.T91S Yes x
ST6GALNAC3 1p31.1 SG c.874A>T p.K292X x
ZAP70 2q11.2 NS c.920C>T p.P307L Yes x
MYO7A 11q13.5 NS c.3126G>T p.W1042C Yes x
CDH5 16q21 NS c.1738G>A p.E580K Yes x
PPP2R1A 19q13.41 NS c.28C>A p.L10M CGC Yes x
WDR52 3q13.2 FS del c.2513delA p.N838fs x
BRD8 5q31.2 SG c.1921G>T p.E641X x
PT ID 8 NCKAP5 2q21.2 S c.1757-2A>G x
VCAN 5q14.3 NS c.2539G>C p.E847Q Yes x
ARID1B 6q25.3 NS c.3607G>T p.A1203S Yes x
OR1K1 9q33.2 NS c.160C>A P.P54T Yes x
NLK 17q11.2 NS c.230C>T p.A77V Yes x
DOCK6 19p13.2 NS c.2338C>A p.L780M Yes x
GSG1L 16p12.1 SG c.507C>A p.C169X x
PT ID 11 SPSB1 1p36.22 NS c.442C>T p.R148W Yes x
OR2M4 1q44 NS c.745G>A p.G249R Yes x
CTNNA2 2p12 NS c.625G>A p.A209T KEGG Yes x
ITPR1 3p26.1 NS c.7915G>A p.E2639K Yes x
PTPN13 4q21.3 NS c.3015G>T p.M1005I Yes x
GPRC6A 6q22.1 NS c.1637G>T p.R546I Yes x
CSPP1 8q13.2 FS del c.2032delA p.K678fs x
UBE3B 12q24.11 NS c.3073G>C p.E1025Q Yes x
HS3ST3A1 17p12 NS c.1132G>A p.E378K Yes x
UBE2O 17q25.1 NS c.1661C>T p.S554L Yes x
PTGIS 20q13.13 NS c.907C>T p.P303S Yes x
PI4KA 22q11.21 NS c.1939G>A p.V647M Yes x
APOL5 22q12.3 S c.142+1G>A x
ZNRF3 22q12.1 NS c.1291C>G p.H431D Yes x
VWF 12p13.31 NS c.1471C>T p.R491C Yes x
PT ID 15 DCC 18q21.2 NS c.151A>G p.T51A KEGG Yes x
PT ID 46 TMPRSS11A 4q13.2 SG c.282G>A p.W94X x
TIAM2 6q25.3 NS c.1627G>T p.G543C Yes x
TIAM2 6q25.3 NS c.1671C>A p.F557L Yes x
A2M 12p13.31 NS c.943G>A p.E315K Yes x
DCC 18q21.2 NS c.3242G>C p.G1081A KEGG Yes x
FCGBP 19q13.2 SG c.14279C>G p.S4760X x
AA change: amino acid change. ALNM: axillary lymph node metastasis. DM: asynchronous distant metastasis. BAF: B allele frequency. Del: deletion. CGS: Cosmic
Cancer Gene Census. FS: frameshift. NS: non-synonymous missense. S: splicing. SG: stopgain. KEGG: KEGG cancer pathway.
https://doi.org/10.1371/journal.pone.0189887.t009
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expanded mutations are detectable in a study like the present and therefore, a detected muta-
tion either confers a selective advantage or is a passenger in a successful clone. Hence, for a
mutation in Category 2 to be a driver of metastatic progression it should be advantageous both
at the primary tumor site and in the metastatic setting. This is indeed possible for some meta-
static abilities such as invasion or angiogenesis. Thus, Category 2 most likely also contains
metastasis progression drivers.
Different gene sets are affected by mutations at different steps of malignant progression. In
Category 1, the top five KEGG pathways included Homologous recombination and Mismatch
repair. These pathways are intuitively relevant for carcinogenesis, the early stages of malig-
nancy. Category 2 is significantly enriched for genes participating in various cancer related
pathways. The Adherens junction pathway is affected by mutations exclusively in the metasta-
ses of three of the studied patients. Adherens junctions are the most common type of intercel-
lular adhesion and limits cell movement and proliferation and are therefore likely to play a key
role in the metastatic process. Metastasis-enabling mutations may, as discussed, be present
already within the primary tumor. Hence, it seems relevant to include both Category 2 and
Category 3 genes in a pathway analysis, revealing the Adherens junction pathway to be signifi-
cantly affected in the primary tumors and metastases of the studied patients.
Recurrently mutated genes among the studied patients are highly likely cancer drivers.
Three genes, BRCA2, RUNX1 and ABCA13 are affected by recurrent mutations both within
patients and among patients and are previously described in relation to cancer [28–30]. The
established cancer gene PIK3CA [31] is affected in all tumor steps of two of the studied
patients. Focusing on metastases, the ABCA13,DCC and TIAM2 genes deserve mention. The
ABCA13 gene is, in addition to mutations in all tumor steps of PTID 123, affected by a frame-
shift deletion exclusively in the metastases of PTID 4. An association has been found between
ATP-binding cassette transporter genes like ABCA13 and outcome in breast cancer patients,
most likely due to their role in drug resistance [30]. The DCC gene, mutated exclusively in
metastases of two of the studied patients (PTID 15 and 46), most likely plays a role in the meta-
static phenotype. Studies in Drosophila have suggested that the DCC gene functions as an inva-
sive tumor suppressor [32,33]. In a murine model of p53 deficient mammary carcinoma cells
it has been reported that additional loss of DCC promotes metastasis formation without affect-
ing the primary tumor phenotype [34] suggesting that the gene limits survival of disseminated
tumor cells. The TIAM2 gene is affected by two non-synonymous mutations exclusively in the
metastasis of PT ID 46. TIAM2S expression is reported to be positively associated with meta-
static phenotype of hepatocellular carcinoma cells and the gene product reported to promote
growth and invasiveness [35]. In vivo studies revealed that TIAM2S expression resulted in up-
regulation of N-cadherin and vimentin and redistribution of E-cadherin [35]. Thus, the
TIAM2 gene is found to function as an oncogene promoting epithelial-to-mesenchymal transi-
tion. In order for the gene to function as a progression driver in the metastatic cells in our
study, the non-synonymous mutations identified in the gene should be activating mutations.
A number of genes are found to be recurrently mutated within individual patient samples.
This phenomenon could be suspected to result from false positive calls. However, in this study,
validation includes sequencing with a mean read depth of 465 x and called positions were
manually curated, ensuring high quality of the reported findings. Whether recurrently mutated
genes within a tumor specimen are situated in cis or in trans and whether they originate from
the same or different cancer cell subclones cannot be established. Two inactivating mutations
located at different alleles within the same cancer cells result in a total inactivation of the gene.
Conversely, if two cancer subclones are affected by different mutations in the same gene this
again suggests a strong selective advantage of mutations in the gene.
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From the list of putative drivers of metastatic progression found only among the metastasis
specific mutations the CREBBP, BCL6B and the ZNF185 genes are the most notable. The
CREBBP gene, mutated exclusively in the metastases of PTID 4, is an epigenetic modifier act-
ing as a transcriptional coactivator through acetylation of histone proteins, thereby securing
transcription of genes, including tumor suppressor genes and has thus been suggested as
tumor suppressor [36]. The BCL6B gene, affected by a frameshift deletion exclusively in both
metastases of PTID 4, is recently reported a novel tumor suppressor gene in hepatocellular car-
cinoma [37]. The BCL6B gene functions as a sequence-specific transcriptional repressor in the
nucleus and is ubiquitously expressed in human tissue. Stable expression of the gene in hepato-
cellular cell lines was found to suppress cell migration and invasion and significantly reduced
the incidence and severity of lung metastases in a mouse model [37]. The anti-metastatic effect
of BCL6Bwas mediated by up-regulation of cell adhesion molecules like E-cadherin and
down-regulation of the angiogenesis gene VEGFA [37]. The ZNF185 gene, affected by a splic-
ing mutation specifically in both metastases of PTID 4, is suggested to function as a tumor sup-
pressor by associating with the actin-cytoskeleton and is reported to be associated with
metastatic progression in colon and prostate cancer [38,39].
The studied cancer genomes most likely represent highly aggressive and treatment insensi-
tive cases and the reported mutational spectrum is highly influenced by the selective pressures
provided by treatment. Some of the mutations may play a role in therapy resistance. Mutations
in the RUNX1 gene is previously reported to correlate with aromatase inhibition resistance
[40]. Our study supports this finding as, in two of the six studied patients, the RUNX1 gene is
affected by mutations in all tumor steps and the patients experienced progression of the disease
in spite of treatment with the aromatase inhibitor Letrozole.
The prioritization among missense mutations for the identification of cancer driver genes
is extremely challenging and no software tool can perform the distinction flawlessly. Thus, the
use of the iCAGES software is just one way one could address this task.
The present study, like most other, focuses on non-synonymous mutations, as synonymous
mutations are widely considered nonfunctional in cancer. However, a relatively recent study
provides evidence that such silent mutations can actually act as oncogenic drivers by altering
transcript splicing and therefore affect protein function [41]. In contrast to what was previ-
ously known, it is found that natural selection also acts on synonymous sites as it was found
that oncogenes, in addition to being enriched for activating missense mutations, were also
enriched for synonymous mutations compared to non-cancer genes [41]. A strong association
was found between synonymous mutations and differential exon usage profiles in the most
recurrently mutated oncogenes. Generally, tumor suppressor genes did not display the same
phenomenon, except TP53which also had recurrent synonymous mutations that, in contrast
to those in oncogenes, were adjacent to splice sites and inactivate them [41]. The study found
synonymous mutations to be nonrandomly distributed across the cancer genome and that
they preferentially targeted evolutionary conserved sites. Hence, synonymous mutations
might confer a selective advantage to the malignant cells. In our study, we do not find evidence
of selective forces acting on synonymous mutations, however, this does not preclude that a few
of the identified synonymous mutations actually do function as a progression driver.
In summary, we report substantial mutational discordance between different steps of malig-
nant progression in the studied breast cancer patients. Putative novel drivers of malignant pro-
gression are reported among the genes mutated exclusively in the metastases and among the
genes shared between the primary tumors and metastases. Most notable are the DCC,TIAM2,
CREBBP, BCL6B and the ZNF185 genes, mutated exclusively in the metastases of the studied
patients and highly likely driver genes of metastatic progression. High NS:S ratios reveal posi-
tive selection of non-synonymous mutations and that more than a few driver genes confer a
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selective advantage in the studied primary tumors. Different genes and pathways are involved
at different stages of breast cancer. The Adherens junction pathway is affected in four of the
six studied patients and this pathway most likely plays a vital role in the metastatic process.
The considerable amount of additional mutations in the asynchronous metastases in several of
the studied patients stresses the importance of molecular profiling of metastatic tissue at recur-
rence of breast cancer in order to provide the optimal basis for personalized medicine.
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